Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma Journal Article
| Authors: | Radivoyevitch, T.; Dean, R. M.; Shaw, B. E.; Brazauskas, R.; Tecca, H. R.; Molenaar, R. J.; Battiwalla, M.; Savani, B. N.; Flowers, M. E. D.; Cooke, K. R.; Hamilton, B. K.; Kalaycio, M.; Maciejewski, J. P.; Ahmed, I.; Akpek, G.; Bajel, A.; Buchbinder, D.; Cahn, J. Y.; D'Souza, A.; Daly, A.; DeFilipp, Z.; Ganguly, S.; Hamadani, M.; Hayashi, R. J.; Hematti, P.; Inamoto, Y.; Khera, N.; Kindwall-Keller, T.; Landau, H.; Lazarus, H.; Majhail, N. S.; Marks, D. I.; Olsson, R. F.; Seo, S.; Steinberg, A.; William, B. M.; Wirk, B.; Yared, J. A.; Aljurf, M.; Abidi, M. H.; Allewelt, H.; Beitinjaneh, A.; Cook, R.; Cornell, R. F.; Fay, J. W.; Hale, G.; Chakrabarty, J. H.; Jodele, S.; Kasow, K. A.; Mahindra, A.; Malone, A. K.; Popat, U.; Rizzo, J. D.; Schouten, H. C.; Warwick, A. B.; Wood, W. A.; Sekeres, M. A.; Litzow, M. R.; Gale, R. P.; Hashmi, S. K. |
| Article Title: | Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma |
| Abstract: | Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM. © 2018 |
| Keywords: | adult; cancer chemotherapy; controlled study; aged; middle aged; young adult; major clinical study; busulfan; disease course; cancer risk; cytarabine; follow up; cancer incidence; disease association; multiple myeloma; etoposide; clinical assessment; cohort analysis; cyclophosphamide; melphalan; carmustine; hodgkin disease; myelodysplastic syndrome; nonhodgkin lymphoma; whole body radiation; transplantation conditioning; cancer registry; intermethod comparison; anthracycline; autologous hematopoietic stem cell transplantation; longitudinal study; aml; mds; acute myeloid leukemia; seer; autotransplant; therapy-related; very elderly; human; male; female; priority journal; article; cibmtr; new cancers |
| Journal Title: | Leukemia Research |
| Volume: | 74 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2018-11-01 |
| Start Page: | 130 |
| End Page: | 136 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2018.07.016 |
| PUBMED: | 30055822 |
| PROVIDER: | scopus |
| PMCID: | PMC6219911 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 December 2018 -- Source: Scopus |
